NASDAQ: SDGRSchrodinger Inc Stock
$26.19+0.44 (+1.71%)
Updated Apr 21, 2025
SDGR Price
$26.19
Fair Value Price
N/A
Market Cap
$1.91B
52 Week Low
$16.60
52 Week High
$28.47
P/E
-10.19x
P/B
4.54x
P/S
6.75x
PEG
N/A
Dividend Yield
N/A
Revenue
$207.54M
Earnings
-$187.12M
Gross Margin
63.6%
Operating Margin
-89.48%
Profit Margin
-90.2%
Debt to Equity
0.95
Operating Cash Flow
-$157M
Beta
1.65
Next Earnings
Apr 29, 2025
Ex-Dividend
N/A
Next Dividend
N/A
SDGR Overview
Schrödinger, Inc., together with its subsidiaries, provides physics-based software platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on selling its software for drug discovery in the life sciences industry, as well as to customers in materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine SDGR's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
SDGR
Ranked#35 of 44
Ranked#35 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $145.27 | A | |
| $60.48 | A | |
| $1.36 | B |
Be the first to know about important SDGR news, forecast changes, insider trades & much more!
SDGR News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how SDGR scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
SDGR is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
SDGR is poor value based on its book value relative to its share price (4.54x), compared to the US Health Information Services industry average (3.29x)
P/B vs Industry Valuation
SDGR is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more SDGR due diligence checks available for Premium users.
Valuation
SDGR price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-10.19x
Industry
10.54x
Market
27.14x
SDGR price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.54x
Industry
3.29x
SDGR is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
SDGR's financial health
Profit margin
Revenue
$88.3M
Net Income
-$40.2M
Profit Margin
-45.5%
SDGR's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
SDGR's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$823.2M
Liabilities
$401.8M
Debt to equity
0.95
SDGR's short-term assets ($634.99M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
SDGR's short-term assets ($634.99M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
SDGR's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
SDGR's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$31.1M
Investing
$23.5M
Financing
$119.0k
SDGR's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
SDGR vs Health Information Service Stocks
Schrodinger Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.